MART-1 Antigen

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

Also Known As:

Networked: 930 relevant articles (16 outcomes, 81 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Romero, Pedro: 31 articles (09/2014 - 03/2002)
2.	Speiser, Daniel E: 25 articles (09/2014 - 03/2002)
3.	Guillaume, Philippe: 19 articles (06/2012 - 03/2002)
4.	Cerottini, Jean-Charles: 19 articles (03/2007 - 03/2002)
5.	Rufer, Nathalie: 16 articles (09/2014 - 10/2002)
6.	Jotereau, Francine: 15 articles (03/2012 - 09/2002)
7.	Rimoldi, Donata: 14 articles (09/2010 - 03/2002)
8.	Baumgaertner, Petra: 11 articles (11/2012 - 07/2006)
9.	Rivoltini, Licia: 10 articles (01/2015 - 10/2002)
10.	Jasiulionis, Miriam G: 10 articles (01/2013 - 04/2005)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 12/01/2002 - "An antibody panel consisting of Mitf and Melan-A is superior to a panel of S-100 and HMB-45 in the diagnosis of melanoma in cytologic specimens." 08/01/2004 - "Our results suggest that the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival." 05/01/2002 - "Melan-A, in particular, may be helpful for the cytological diagnosis of canine melanoma." 10/01/2001 - "While there were no positive results in localized disease (stages I and II), identification of specific PCR products in stage III melanoma patients was restricted to the MART-1/Melan-A tests, with positive results in 11% (two out of 19) of the blood specimens analysed. " 09/01/2013 - "Additional immunohistochemistry studies confirmed immunoreactivity for CD68, CD45, CD45RO, and CD15 and were negative for CD3, CD20, melanoma cocktail, CD30, CD1a, CD34, HMB-45, and melan-A. "
2.	Neoplasms (Cancer) 12/01/2013 - "Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials." 11/15/2002 - "In this study, we have analyzed the recognition of sequences retrieved by using a biometric analysis of the data generated by screening a PS-SCL with a tumor-reactive CTL clone specific for an immunodominant peptide from the melanocyte differentiation and tumor-associated Ag Melan-A. " 12/01/2001 - "Immunohistochemical studies showed reactivity to the anti-Melan-A A103 antibody, suggesting an adrenal origin of the tumor cells. " 01/01/2016 - "There is variable positivity for HMB-45, MelanA, MiTF, and CathepsinK, and some tumors have been shown to express TFE-3 especially when associated with "clear cell" morphology. " 11/01/2015 - "The authors therefore performed immunohistochemical analyses of tumor cell proliferation (Melan-A/Ki67) and infiltration of inflammatory cells (CD66b neutrophils and CD163 macrophages) to better understand the biology of the epidermal changes described. "
3.	Nevus (Nevi) 12/01/2004 - "Melan-A is very useful in distinguishing between DMM and sclerotic nevi. " 02/01/2015 - "Interpretation of nodal nevus staining (negative by HMB-45) was significantly aided by the crisp nuclear staining produced by SOX10 as compared with the obscuring cytoplasmic staining produced by S100 protein and Melan-A in 3 cases. " 02/01/2015 - "SOX10 stained nodal nevi in a similar manner to S100 protein and Melan-A in 4 cases. " 02/01/2012 - "Melan-A immunostains were also used to screen 25 cases of grossly normal fetal skin for occult fetal nevi. " 12/01/2004 - "In contrast, 100% of the 13 nevi were strongly positive for Melan-A (P < 0.001). "
4.	Pigmented Nevus (Melanocytic Nevus) 10/01/2012 - "melanocytic nevi, because of their histopathologic attributes (symmetric silhouette, benign cytologic features) and results from immunohistochemical studies (all lesions strongly expressed Melan-A and p16) and fluorescence in situ hybridization (FISH). " 07/01/2012 - "Our data indicate that Melan-A immunohistochemical staining is helpful in differentiating neurotized melanocytic nevi from neurofibromas when distinction on histomorphology alone is difficult." 07/01/2012 - "All of the melanocytic nevi showed Melan-A staining within the neurotized areas, with most of the areas staining strongly positive, whereas all the neurofibromas were completely absent of Melan-A stain. " 07/01/2012 - "To determine whether Melan-A (MART-1) immunohistochemical stain is sufficient to differentiate neurotized melanocytic nevi from neurofibromas. " 07/01/2012 - "Differentiating neurotized melanocytic nevi from neurofibromas using Melan-A (MART-1) immunohistochemical stain."
5.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 02/01/2003 - "In this study we investigated the level of efficacy of a MART-1/Melan-A-specific CD8+ T cell clone against its autologous melanoma in a severe combined immunodeficiency (SCID) mouse model, in which the tumor cells expressed in vivo heterogeneous and suboptimal levels of MART-1. "

Related Drugs and Biologics

1.	Monophenol Monooxygenase (Tyrosinase)
2.	Antigens
3.	Messenger RNA (mRNA)
4.	S100 Proteins (S 100 Protein)
5.	HLA-A2 Antigen (HLA A2 Antigen)
6.	Peptides
7.	Keratins (Keratin)
8.	Epitopes
9.	Desmin
10.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Immunotherapy
2.	Nerve Transfer
3.	Mohs Surgery (Mohs' Micrographic Surgery)
4.	Lymph Node Excision (Lymph Node Dissection)
5.	Stents